中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1249 records (took 0.074 seconds)

    NANOPARTICLE-ASSISTED ULTRASOUND FOR CANCER THERAPY
    132.
    发明申请
    NANOPARTICLE-ASSISTED ULTRASOUND FOR CANCER THERAPY 有权
    用于癌症治疗的纳米辅助超声波治疗

    公开(公告)号：US20140335156A1

    公开(公告)日：2014-11-13

    申请号：US14253977

    申请日：2014-04-16

    Applicant: Academia Sinica

    Inventor： Olga K. Kosheleva ,  Peter Lai ,  Nelson G. Chen ,  Michael Hsiao ,  Chung-Hsuan Chen

    IPC: A61K9/00

    CPC classification number: A61K41/0033 ,  A61K41/0028 ,  A61K47/6923 ,  A61N7/00 ,  A61N7/02 ,  Y10S977/773 ,  Y10S977/911

    Abstract: Methods for killing cancer cells and treating cancer in a subject by exposing the cells to nanoparticles, and irradiating with a focused, low to medium power ultrasound. The nanoparticles can be gold, iron oxide, copper, silver, polystyrene, PEG, or liposome nanoparticles. The nanoparticles can have a cancer drug attached, such as an antibody-based cancer drug.

    Abstract translation: 通过将细胞暴露于纳米颗粒并用聚焦的低至中等功率超声照射来杀死受试者的癌细胞和治疗癌症的方法。 纳米颗粒可以是金，氧化铁，铜，银，聚苯乙烯，PEG或脂质体纳米颗粒。 纳米颗粒可以具有连接的癌症药物，例如基于抗体的癌症药物。

    Multiplex barcoded paired-end diTag (mbPED) sequencing approach and ITS application in fusion gene identification
    133.
    发明授权
    Multiplex barcoded paired-end diTag (mbPED) sequencing approach and ITS application in fusion gene identification 有权
    多重条码配对端diTag（mbPED）测序方法和ITS在融合基因鉴定中的应用

    公开(公告)号：US08829172B2

    公开(公告)日：2014-09-09

    申请号：US13416764

    申请日：2012-03-09

    Applicant: Kuo Ping Chiu ,  Yi Chou ,  Sheng-Chung Chen

    Inventor： Kuo Ping Chiu ,  Yi Chou ,  Sheng-Chung Chen

    IPC: C07H21/00 ,  G01N33/487 ,  C12P19/34 ,  C12N15/66 ,  C12N15/65

    CPC classification number: C12N15/66 ,  C12N15/65 ,  C12P19/34

    Abstract: A method of generating a barcoded Paired-End Ditag (bPED) nucleic acid fragment is disclosed. The method comprises: a) performing a first ligation by ligating a half-adaptor with one or two 3′-overhanging ends to a target nucleic acid to obtain a nucleic acid fragment with two ends each attached to one of the half-adaptor, the half adaptor comprising a half-barcode and a restriction enzyme (RE) recognition site; b) performing a second ligation by ligating two of the half-adaptor at the two ends of the nucleic acid fragment to form a circularized nucleic acid construct, wherein the circularized nucleic acid construct comprises a full-size barcoded adaptor; and c) digesting the circularized nucleic acid construct with a RE that cleaves at a defined distance from the RE recognition site, and thereby generating the bPED nucleic acid fragment.

    Abstract translation: 公开了一种产生条形码配对末端分析（bPED）核酸片段的方法。 该方法包括：a）通过将半适配子与一个或两个3'-突出末端连接至靶核酸来进行第一次连接，以获得核酸片段，其两端分别连接到半适配器之一， 半适配器，其包含半条形码和限制酶（RE）识别位点; b）通过在核酸片段的两端连接两个半连接体以形成环化的核酸构建体来进行第二次连接，其中所述环化的核酸构建体包含全尺寸条形码适配器; 和c）用在RE识别位点定义的距离处切割的RE消化环化的核酸构建体，从而产生bPED核酸片段。

    Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes
    136.
    发明授权
    Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes 有权
    能够结合B淋巴细胞上的人类mIgE的抗C＆amp; mX抗体

    公开(公告)号：US08741294B2

    公开(公告)日：2014-06-03

    申请号：US13888913

    申请日：2013-05-07

    Applicant: Academia Sinica

    Inventor： Tsewen Chang ,  Jiun-Bo Chen ,  Pheidias C. Wu ,  Alfur F. Hung

    IPC: A61K39/395 ,  C07K16/42

    CPC classification number: C07K16/2803 ,  A61K39/39566 ,  C07K16/4291 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/862 ,  Y10S530/868

    Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to CεmX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The CεmX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of CεmX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of CεmX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.

    Abstract translation: 本发明涉及能够在人B淋巴细胞表面表达的膜结合IgE（mIgE）上有效结合C＆amp; mX结构域的抗体的产生和应用。 已经提出位于人膜结合的ε链上的CH4结构域和C末端膜锚定肽之间的52个氨基酸残基的Cys区域作为用于免疫靶向表达mIgE的B细胞的抗原位点。 目前已经发现，以前报道的，在C细胞C末端结合RADWPGPP（SEQ ID NO：1）肽的单克隆抗体，包括a20，现在已被发现与人B细胞上的mIgE结合不良。 我们已经发现，对于某些片段（例如GLAGGSAQSQRAPDRVL（SEQ ID NO：2）和HSGQQQGLPRAAGGSVPHPR（SEQ ID NO：3））特异性的单克隆抗体，C＆amp; mX可以有效地结合到人B细胞上的mIgE，因此具有效用 用于靶向这些B细胞用于治疗由IgE介导的疾病。

    METHODS OF DIAGNOSING, PREDICTING AND TREATING CARDIOVASCULAR DISEASE
    137.
    发明申请
    METHODS OF DIAGNOSING, PREDICTING AND TREATING CARDIOVASCULAR DISEASE 审中-公开
    诊断，预防和治疗心血管疾病的方法

    公开(公告)号：US20140120551A1

    公开(公告)日：2014-05-01

    申请号：US14064511

    申请日：2013-10-28

    Applicant: ACADEMIA SINICA

    Inventor： RUEY-BING YANG ,  TE-FA CHIU

    IPC: G01N33/68

    CPC classification number: G01N33/6893 ,  G01N2800/324

    Abstract: Methods for determining an increased risk of developing a cardiovascular event excluding stable angina in a subject are disclosed. Also disclosed are methods for diagnosing a human subject's myocardial infarction (MI) and/or acute coronary syndrome (ACS) state or identifying a human subject's risk of MI and/or ACS.

    Abstract translation: 公开了用于确定在受试者中排除稳定性心绞痛的发展心血管事件的风险增加的方法。 还公开了用于诊断人受试者的心肌梗死（MI）和/或急性冠状动脉综合征（ACS）状态或鉴定人受试者的MI和/或ACS的风险的方法。

Patent Agency Ranking